CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 46 enrolled
Drug / intervention
Ropivacaine injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03316378
NCT03316378Phase 3Completed

Impact of Peripheral Pain Perception on Central Sensitization and Movement Strategies in Patients With Chronic Achilles Tendinopathy

Ruth Chimenti·interventional·Posted Oct 20, 2017·Updated Jul 5, 2019

In Brief

A Phase 3 clinical trial evaluating Ropivacaine injection for Achilles Tendon Pain. Completed, enrolled 46 participants across 1 site.

Detailed Summary

The purpose of this study is to better understand how the peripheral and central nervous system interact to produce the sensation of pain and motor patterns in patients with achilles tendinopathy (AT). These findings will motivate the development of future clinical studies that incorporate knowledge about pain processing and movement strategies in patients with tendinopathy. Participants with achilles tendinopathy will receive an anesthetic injection to the achilles tendon in order to examine how reduced pain, detected by the peripheral nervous system, alters task performance and perception of pain. We hypothesize that there are factors within the central nervous system that contribute to continued pain and disability in patients with chronic AT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 20, 2017
Enrollment StartJan 28, 2016
Primary CompletionMay 10, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.7 years ago

Interventions

Ropivacaine injectiondrug

single dose, subcutaneous injection